Format

Send to

Choose Destination
See comment in PubMed Commons below
Expert Rev Cardiovasc Ther. 2008 Jan;6(1):17-25.

Ezetimibe plus simvastatin cardiovascular outcomes study program.

Author information

1
Cardiac Unit, Hospital Virgen de la Salud, Avda. Barber, 30, 45004 Toledo, Spain. lrodriguez@sescam.org

Abstract

Ezetimibe is a drug that impairs intestinal cholesterol absorption and decreases blood cholesterol levels. It has been shown that added to statins it can achieve a further reduction of low-density lipoprotein-cholesterol of 18-20%, overcoming the increase in absorption that follow the reduction in cholesterol synthesis by statins. Four major outcome trials are underway to study the effect of ezetimibe plus simvastatin in different subsets of high-risk patients: familiar hypercholesterolemia, degenerative aortic stenosis, chronic kidney disease and acute coronary syndrome. Hopefully, in the next few years the information provided by these trials will allow us to further reduce the increasing burden of cardiovascular disease.

PMID:
18095904
DOI:
10.1586/14779072.6.1.17
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center